Released Mar 17, 2022, after the close
10-Q filed Mar 17, 2022, 45 days after period end · 0001654954-22-003371
Q1 2022 · 10-Q
Revenue$5.02M$5.02M +11.8% vs Q1 2021−10.3% vs Q4 2021
Net Income$305.24K$305.24K +13.9% vs Q1 2021N/M vs Q4 2021
EPS, diluted—
Gross Profit$1,244,583−5.4%
Operating Income$355,848+11.5%
Operating Cash Flow-$327,202N/M
Free Cash Flowderived-$327,886N/M
Margins · derived
Gross margin24.8%−4.5 pt vs Q1 2021
Operating margin7.1%−0.0 pt vs Q1 2021
Net margin6.1%+0.1 pt vs Q1 2021
What the release said
The release
Same quarter
| Metric | Q1 2022 | Q1 2021 | Q1 2020 | Q1 2019 |
|---|---|---|---|---|
| Revenue | $5.02M | $4.49M | $4.61M | $4.57M |
| Net Income | $305.24K | $268.03K | $526.90K | $471.02K |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pharma-Bio Serv, Inc. · CIK 1304161 · Engraved from SEC EDGAR